|
1
|
Sun XD, Mu R, Zhou YS, Dai XD, Zhang SW,
Huangfu XM, Sun J, Li LD, Lu FZ and Qiao YL: Analysis of mortality
rate of stomach cancer and its trend in twenty years in China.
Zhonghua Zhong Liu Za Zhi. 26:4–9. 2004.(In Chinese). PubMed/NCBI
|
|
2
|
Patru CL, Surlin V, Georgescu I and Patru
E: Current issues in gastric cancer epidemiology. Rev Med Chir Soc
Med Nat Iasi. 117:199–204. 2013.PubMed/NCBI
|
|
3
|
Khan MI, Baqai MT, Bukhari M and Hashmi
RI: Gastric carcinoma: 5 years survival after gastric surgery. J
Pak Med Assoc. 55:158–160. 2005.PubMed/NCBI
|
|
4
|
Dunn GP, Old LJ and Schreiber RD: The
three Es of cancer immunoediting. Annu Rev Immunol. 22:329–360.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Verreck FA, de Boer T, Langenberg DM,
Hoeve MA, Kramer M, Vaisberg E, Kastelein R, Kolk A, de
Waal-Malefyt R and Ottenhoff TH: Human IL-23-producing type 1
macrophages promote but IL-10-producing type 2 macrophages subvert
immunity to (myco)bacteria. Proc Natl Acad Sci USA. 101:4560–4565.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kabelitz D, Wesch D and He W: Perspectives
of gammadelta T cells in tumor immunology. Cancer Res. 67:5–8.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Casetti R and Martino A: The plasticity of
gamma delta T cells: innate immunity, antigen presentation and new
immunotherapy. Cell Mol Immunol. 5:161–170. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Born WK, Reardon CL and O'Brien RL: The
function of gammadelta T cells in innate immunity. Curr Opin
Immunol. 18:31–38. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Harris KM: Monocytes differentiated with
GM-CSF and IL-15 initiate Th17 and Th1 responses that are
contact-dependent and mediated by IL-15. J Leukoc Biol. 90:727–734.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Barilli A, Rotoli BM, Visigalli R,
Bussolati O, Gazzola GC, Kadija Z, Rodi G, Mariani F, Ruzza ML,
Luisetti M and Dall'Asta V: In lysinuric protein intolerance system
y+l activity is defective in monocytes and in GM-CSF-differentiated
macrophages. Orphanet J Rare Dis. 5:322010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Moser B and Brandes M: Gammadelta T cells:
an alternative type of professional APC. Trends Immunol.
27:112–118. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kobayashi H, Tanaka Y, Yagi J, Osaka Y,
Nakazawa H, Uchiyama T, Minato N and Toma H: Safety profile and
anti-tumor effects of adoptive immunotherapy using gamma-delta T
cells against advanced renal cell carcinoma: a pilot study. Cancer
Immunol Immunother. 56:469–476. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bennouna J, Bompas E, Neidhardt EM,
Rolland F, Philip I, Galéa C, Salot S, Saiagh S, Audrain M, Rimbert
M, et al: Phase-I study of Innacell gammadelta, an autologous
cell-therapy product highly enriched in gamma9delta2 T lymphocytes,
in combination with IL-2, in patients with metastatic renal cell
carcinoma. Cancer Immunol Immunother. 57:1599–1609. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen FX, Liu JQ, Xia F, Zhang J and Zhang
S: A new method for the amplification of human γδT cells. Chin Cell
Mol Immunol. 23:662–664. 2007.(In Chinese).
|
|
15
|
Liu JQ: The detection of LAK cell activity
by LDH kit. Chin J Clin Lab Sci. 13:831995.(In Chinese).
|
|
16
|
Smith PD, Ochsenbauer-Jambor C and
Smythies LE: Intestinal macrophages: Unique effector cells of the
innate immune system. Immunol Rev. 206:149–159. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Baron-Bodo V, Doceur P, Lefebvre ML,
Labroquère K, Defaye C, Cambouris C, Prigent D, Salcedo M, Boyer A
and Nardin A: Anti-tumor properties of human-activated macrophages
produced in large scale for clinical application. Immunobiology.
210:267–277. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wallace PK, Romet-Lemonne JL, Chokri M,
Kasper LH, Fanger MW and Fadul CE: Production of
macrophage-activated killer cells for targeting of glioblastoma
cells with bispecific antibody to FcgammaRI and the epidermal
growth factor receptor. Cancer Immunol Immunother. 49:493–503.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Solinas G, Germano G, Mantovani A and
Allavena P: Tumor-associated macrophages (TAM) as major players of
the cancer-related inflammation. J Leukoc Biol. 86:1065–1073. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gordon S: Alternative activation of
macrophages. Nat Rev Immunol. 3:23–35. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kondo M, Izumi T, Fujieda N, Kondo A,
Morishita T, Matsushita H and Kakimi K: Expansion of human
peripheral blood gammadelta T cells using zoledronate. J Vis Exp.
Sep 9–2011.(Epub ahead of print). View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Beck BH, Kim HG, Kim H, Samuel S, Liu Z,
Shrestha R, Haines H, Zinn K and Lopez RD: Adoptively transferred
ex vivo expanded gammadelta-T cells mediate in vivo antitumor
activity in preclinical mouse models of breast cancer. Breast
Cancer Res Treat. 122:135–144. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kondo M, Sakuta K, Noguchi A, Ariyoshi N,
Sato K, Sato S, Sato K, Hosoi A, Nakajima J, Yoshida Y, et al:
Zoledronate facilitates large-scale ex vivo expansion of functional
gammadelta T cells from cancer patients for use in adoptive
immunotherapy. Cytotherapy. 10:842–856. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yuasa T, Sato K, Ashihara E, Takeuchi M,
Maita S, Tsuchiya N, Habuchi T, Maekawa T and Kimura S:
Intravesical administration of gammadelta T cells successfully
prevents the growth of bladder cancer in the murine model. Cancer
Immunol Immunother. 58:493–502. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Viey E, Fromont G, Escudier B, Morel Y, Da
Rocha S, Chouaib S and Caignard A: Phosphostim-activated gamma
delta T cells kill autologous metastatic renal cell carcinoma. J
Immunol. 174:1338–1347. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Han LY, Fei SJ, Chen FX, Liu JQ and Chen
GL: Effect of zoledronate on human γδT cells killing gastric cancer
cell lines SGC-7901. World Chin Digestol. 17:181–185. 2009.(In
Chinese). View Article : Google Scholar
|
|
27
|
Dalton JE, Pearson J, Scott P and Carding
SR: The interaction of gamma delta T cells with activated
macrophages is a property of the V gamma 1 subset. J Immunol.
171:6488–6494. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dalton JE, Howell G, Pearson J, Scott P
and Carding SR: Fas-Fas ligand interactions are essential for the
binding to and killing of activated macrophages by gamma delta T
cells. J Immunol. 173:3660–3667. 2004. View Article : Google Scholar : PubMed/NCBI
|
